Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

checkorphan
Learn more about:
Central serous chorioretinopathy
Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Official Title

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Brief Summary

      Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Detailed Description

      Brinzolamide is a carbonic anhydrase inhibitor. Previously, carbonic anhydrase inhibitors
      have been shown to be effective for the treatment of macular edema when administered orally,
      also for central serous chorioretinopathy. However, this treatment carries the risk of severe
      side effects.

      The goal of this study is to examine the efficacy of the topical form of treatment of
      carbonic anhydrase inhibitors in patients with chronic, non-resolving, central serous
      chorioretinopathy.

Study Phase

Phase 2

Study Type

Interventional

Primary Outcome

Change in subretinal fluid (microns)

Secondary Outcome

 Change in ETDRS visual acuity (number of letters)

Condition

Central Serous Chorioretinopathy

Intervention

Brinzolamide Ophthalmic

Study Arms / Comparison Groups

 Topical brinzolamide
Description:  Brinzolamide ophthalmic, given bd for 3 months

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

35

Start Date

June 1, 2018

Completion Date

April 1, 2019

Primary Completion Date

January 1, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4
             months of follow-up

          -  Optical coherence tomography (OCT) shows foveal subretinal fluid

          -  Fluorescein angiography and indocyanine green confirm the diagnosis

        Exclusion Criteria:

          -  Any other ophthalmic condition that may lead to subretinal fluid

          -  Choroidal neovascularization

          -  Myopia > -6D

          -  Previous treatment for CSC in the past 6 months

          -  Known allergy to fluorescein or indocyanin green

          -  Known allergy for brinzolamide

          -  Pregnancy, breast feeding

Gender

All

Ages

18 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Dinah Zur, +97236973408, [email protected]

Location Countries

Argentina

Location Countries

Argentina

Administrative Informations

NCT ID

NCT03542006

Organization ID

0647-17

Responsible Party

Principal Investigator

Study Sponsor

Tel-Aviv Sourasky Medical Center

Study Sponsor

Dinah Zur, Principal Investigator, Tel-Aviv Sourasky Medical Center

Verification Date

May 2018